Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 91
Filter
1.
Int J Cosmet Sci ; 39(1): 49-55, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27261166

ABSTRACT

OBJECTIVE: A higher trans-epidermal water loss (TEWL) occurs in rough skin, in elder skin and also in atopic dermatitis. An impaired skin barrier function is considered to be caused by an incomplete construction of the intercellular lamellar structure due to the quantitative reduction of ceramides. Since these symptoms coexist with oxidative stress, we hypothesized that impairment of the skin barrier function is accelerated by oxidative stress. Thus, the purpose of this study was to clarify the effect of oxidative stress on ceramide synthesis and to characterize whether antioxidants can improve skin barrier function. 3-O-Laurylglyceryl ascorbate (VC-3LG), which is a newly amphipathic derivative of ascorbic acid, was evaluated as a candidate antioxidant. METHODS: We characterized the mRNA expression levels of serine palmitoyltransferase (SPT) in normal human epidermal keratinocytes (NHEKs) treated with H2 O2 using real-time PCR analysis. In order to evaluate the effect of VC-3LG on skin barrier function, we used several assays with reconstructed human epidermis equivalents (RHEEs). RESULTS: Ceramide synthesis was down-regulated in NHEKs by oxidative stress. Treatment with VC-3LG abrogated the down-regulation of SPT mRNA in NHEKs caused by oxidative stress, and stimulated SPT mRNA expression levels. In experiments characterizing the antioxidative properties of VC-3LG, VC-3LG reduced oxidative stress in NHEKs by up-regulating catalase mRNA expression. In addition, VC-3LG stimulated the skin barrier function in RHEEs, which had lower TEWL values compared with untreated RHEEs. Furthermore, VC-3LG increased the quantity of ceramide in RHEEs. CONCLUSION: Taken together, we conclude that VC-3LG reinforces the skin barrier function due to its reduction of oxidative stress and its promotion of ceramide synthesis.


Subject(s)
Ascorbic Acid/analogs & derivatives , Ceramides/biosynthesis , Oxidative Stress/drug effects , Skin Absorption/drug effects , Antioxidants/pharmacology , Ascorbic Acid/pharmacology , Cells, Cultured , Humans , PPAR alpha/genetics , RNA, Messenger/genetics , Serine C-Palmitoyltransferase/genetics , Up-Regulation
2.
Transpl Infect Dis ; 18(5): 773-776, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27459097

ABSTRACT

We describe successful treatment of 3 cases of human herpesvirus 6 (HHV-6) encephalitis/myelitis following cord blood transplantation (CBT). Ganciclovir (GCV) (10 mg/kg/day) reduced HHV-6 load to undetectable levels in cerebrospinal fluid (CSF). Early dose reduction in the presence of HHV-6 detectable in CSF resulted in an increased HHV-6 load. GCV was capably shifted to valganciclovir (VGCV) with an almost equivalent concentration. GCV/VGCV may be effective for HHV-6 encephalitis/myelitis after CBT, although HHV-6 load in CSF should be monitored.


Subject(s)
Antiviral Agents/therapeutic use , Encephalitis, Viral/drug therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Herpesvirus 6, Human/isolation & purification , Myelitis/drug therapy , Roseolovirus Infections/drug therapy , Transplantation Conditioning/adverse effects , Viral Load/drug effects , Adult , Antiviral Agents/administration & dosage , Child, Preschool , DNA, Viral , Encephalitis, Viral/cerebrospinal fluid , Encephalitis, Viral/virology , Female , Fetal Blood , Ganciclovir/administration & dosage , Ganciclovir/analogs & derivatives , Ganciclovir/therapeutic use , Humans , Male , Myelitis/cerebrospinal fluid , Myelitis/virology , Myeloablative Agonists/adverse effects , Roseolovirus Infections/cerebrospinal fluid , Roseolovirus Infections/virology , Treatment Outcome , Valganciclovir , Young Adult
3.
Transplant Proc ; 46(3): 794-6, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24767351

ABSTRACT

INTRODUCTION: Once-daily extended-release tacrolimus (Tac-OD) is expected to reduce non-adherence in recipients after liver transplantation (LT). The aim of this study was to determine the optimal initial dose of orally administered Tac-OD after intravenous tacrolimus (Tac-IV) therapy after LT. PATIENTS AND METHODS: This prospective study included 10 adult recipients who had undergone LT at our institute. The recipients were prescribed tacrolimus by continuous intravenous administration with a steroid as initial immunosuppression therapy. Tacrolimus was converted from intravenous administration to once-daily oral intake when gastrointestinal function returned. We evaluated tacrolimus concentrations in blood 9 times a day and area under the blood concentration-time curve (AUC) during conversion. The optimal initial dose of Tac-OD was determined based on simple regression analysis between the oral dose of Tac-OD and the total dose of Tac-IV during a 24-hour period. RESULTS: The AUC before and after conversion showed no differences. We found that the optimal initial dose of Tac-OD was 8 times the dose of Tac-IV. There was a relationship between the AUC and the trough level. No recipients experienced acute rejection or adverse effects such as renal failure, neurotoxicity, or cardiac failure during conversion. CONCLUSIONS: We successfully converted continuous Tac-IV to oral intake of Tac-OD by adjusting the dose using trough levels without acute rejection or adverse effects. The AUC of Tac-OD correlated with the trough level. The optimal initial dose ratio of Tac-OD after Tac-IV was 8:1.


Subject(s)
Immunosuppressive Agents/administration & dosage , Liver Transplantation , Tacrolimus/administration & dosage , Administration, Oral , Area Under Curve , Delayed-Action Preparations , Humans , Prospective Studies
4.
Infection ; 42(4): 639-47, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24567233

ABSTRACT

INTRODUCTION: Micafungin (MCFG) is used for the prophylaxis of invasive fungal disease (IFD) after allogeneic hematopoietic stem cell transplantation (HSCT). However, the safety, efficacy, or optimal dosage/blood levels as prophylaxis is uncertain in pediatric HSCT-patients. METHODS: We prophylactically administered MCFG at 2 mg/kg once daily to 38 children and adolescents undergoing allogeneic HSCT. RESULTS: During MCFG prophylaxis, infusion reactions or adverse events (grades 2-5) related to MCFG use were not found in all the patients. Thus, MCFG prophylaxis was not discontinued and other antifungal agents were not added except for 2 patients in whom probable or possible IFDs developed (completion rate, 94.7 %). To elucidate the influence of HSCT-related complications/drugs on blood concentration of MCFG, we determined the plasma trough and peak levels in 13 and 10 among 38 patients, respectively. The mean trough and peak levels were 3.04 ± 1.21 µg/mL (569 samples) and 9.63 ± 3.62 µg/mL (44 samples), respectively. The peak levels were moderately correlated to the trough levels (R (2) = 0.466). In a patient, the trough level of MCFG transiently increased up to 10.21 µg/mL during hepatic dysfunction due to acute graft-versus-host disease. The MCFG trough levels strongly correlated with T-Bil value (R (2) = 0.894). There was no relationship between the trough levels of MCFG and the circulating concentrations of tacrolimus (R (2) = 0.040). Additionally, MCFG levels were not influenced by treatment with cyclophosphamide or corticosteroids. CONCLUSIONS: Prophylaxis with MCFG at 2 mg/kg once daily may be safe, tolerable, and feasible in pediatric HSCT-patients.


Subject(s)
Antifungal Agents/administration & dosage , Chemoprevention/methods , Echinocandins/administration & dosage , Hematopoietic Stem Cell Transplantation/adverse effects , Lipopeptides/administration & dosage , Mycoses/prevention & control , Adolescent , Antifungal Agents/adverse effects , Antifungal Agents/pharmacokinetics , Chemoprevention/adverse effects , Child , Child, Preschool , Drug-Related Side Effects and Adverse Reactions , Echinocandins/adverse effects , Echinocandins/pharmacokinetics , Female , Humans , Infant , Lipopeptides/adverse effects , Lipopeptides/pharmacokinetics , Male , Micafungin , Plasma/chemistry
5.
Tissue Antigens ; 83(1): 45-8, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24355007

ABSTRACT

A genetic polymorphism of the newly discovered interferon-λ 4 (IFNL4) gene was associated with hepatitis C virus (HCV) clearance in individuals of African ancestry. To assess whether a dinucleotide variant of IFNL4 (ss469415590) also affected treatment outcome of antiviral therapy in Japan, we genotyped 213 patients with chronic genotype 1 HCV infection and 176 healthy subjects. The ΔG allele was associated with treatment failure [odds ratio (OR) 4.73, P = 0.019], as was the IFL3 rs8099917 single nucleotide polymorphism (SNP) (OR 5.06, P = 0.068). The correlation between ss469415590 and rs8099917 was high (r(2) = 0.92, D' = 0.98). Multivariate analysis revealed that the rs8099917 SNP was independently associated with treatment failure (OR 5.28, P = 0.009). Therefore, ss469415590 may be another predictive marker of antiviral therapy outcome in the Japanese population.


Subject(s)
Hepatitis C, Chronic/genetics , Hepatitis C, Chronic/therapy , Interferon-alpha/therapeutic use , Interleukins/genetics , Ribavirin/therapeutic use , Adult , Aged , Aged, 80 and over , Female , Genotype , Hepatitis C, Chronic/diagnosis , Humans , Japan , Male , Middle Aged , Polymorphism, Genetic , Treatment Outcome , Young Adult
6.
Infection ; 41(1): 219-23, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22971937

ABSTRACT

BACKGROUND: There have been no reports of human herpesvirus-6 (HHV-6) encephalitis treatment based on both HHV-6 DNA load and the antiviral agent's concentration in the cerebrospinal fluid (CSF). PATIENT: A 20-year-old male with a hematological malignancy developed HHV-6 encephalitis 15 days after unrelated cord blood transplantation (UCBT). He had fever, chest pain, memory impairment, and insomnia. His CSF showed no increased cell counts, but the amount of HHV-6 DNA was elevated to 2.0 × 10(6) copies/ìgDNA. Magnetic resonance imaging (MRI) of the head revealed abnormal high-intensity signals in the left limbic system on T2-weighted and diffusion-weighted images. Intravenous administration of ganciclovir (GCV) was initiated at 5 mg/kg every 12 h on day 18, and was continued until day 137. The amount of HHV-6 DNA in the plasma became undetectable on day 25. The HHV-6 load in the CSF decreased to 1.5 × 10(3) copies/ìgDNA on day 32, and reached undetectable levels on day 53. The mean concentration of GCV 1 h after an infusion of 5 mg/kg was 4.12 mg/mL in plasma and 0.7 mg/mL in CSF. The chest pain and insomnia disappeared on days 35 and 47, respectively. Memory defects recovered up to day 85. CONCLUSION: Serial quantification of HHV-6 DNA in CSF may be useful for successful treatment with GCV in post-transplant HHV-6 encephalitis.


Subject(s)
Antiviral Agents/therapeutic use , Encephalitis, Viral/drug therapy , Ganciclovir/therapeutic use , Herpesvirus 6, Human/isolation & purification , Roseolovirus Infections/drug therapy , Adult , Brain/pathology , Cord Blood Stem Cell Transplantation/adverse effects , DNA, Viral/cerebrospinal fluid , Encephalitis, Viral/diagnosis , Encephalitis, Viral/virology , Ganciclovir/pharmacokinetics , Humans , Magnetic Resonance Imaging , Male , Roseolovirus Infections/diagnosis , Roseolovirus Infections/virology , Viral Load , Young Adult
7.
Tissue Antigens ; 80(4): 305-16, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22861646

ABSTRACT

Current human leukocyte antigen (HLA) DNA typing methods such as the sequence-based typing (SBT) and sequence-specific oligonucleotide (SSO) methods generally yield ambiguous typing results because of oligonucleotide probe design limitations or phase ambiguity for HLA allele assignment. Here we describe the development and application of the super high-resolution single-molecule sequence-based typing (SS-SBT) of HLA loci at the 8-digit level using next generation sequencing (NGS). NGS which can determine an HLA allele sequence derived from a single DNA molecule is expected to solve the phase ambiguity problem. Eight classical HLA loci-specific polymerase chain reaction (PCR) primers were designed to amplify the entire gene sequences from the enhancer-promoter region to the 3' untranslated region. Phase ambiguities of HLA-A, -B, -C, -DRB1 and -DQB1 were completely resolved and unequivocally assigned without ambiguity to single HLA alleles. Therefore, the SS-SBT method described here is a superior and effective HLA DNA typing method to efficiently detect new HLA alleles and null alleles without ambiguity.


Subject(s)
Genetic Loci , HLA Antigens/analysis , High-Throughput Nucleotide Sequencing/methods , Multilocus Sequence Typing/methods , 3' Untranslated Regions , Alleles , DNA Primers , HLA Antigens/genetics , High-Throughput Nucleotide Sequencing/instrumentation , Humans , Multilocus Sequence Typing/instrumentation , Polymerase Chain Reaction , Promoter Regions, Genetic , Sequence Analysis, DNA
8.
Bone Marrow Transplant ; 46(1): 90-7, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20383212

ABSTRACT

We investigated clinical factors that affected the clearance of tacrolimus (FK506) administered by continuous drip infusion to children who had received allogeneic hematopoietic SCT. Blood FK506 levels were measured every day in 27 patients in an attempt to adjust the dose to maintain the target range (10-15 ng/mL). Patients who developed engraftment syndrome (ES) and acute GVHD and patients less than 7 years of age showed a higher FK506 clearance calculated from body weight (BW) for 5 or more consecutive days compared with the control groups. A time-course study showed that the occurrence of ES, but not acute GVHD, was related to increased clearance of FK506. When calculated from body surface area (BSA), a significant increase in FK506 clearance was observed in patients with ES, but not in those less than 7 years of age. FK506 clearance was not influenced by CYP3A5, multidrug resistance 1 or ABCG2 genotypes. None of the clinical parameters affected blood FK506 levels. Determination of the FK506 dose on the basis of frequent monitoring of the blood concentration seems to minimize the serious adverse effects induced by the immunosuppressant. It may be more accurate to dose FK506 according to BSA rather than BW for pediatric patients.


Subject(s)
Erythema/metabolism , Fever/metabolism , Hematopoietic Stem Cell Transplantation , Immunosuppressive Agents/pharmacokinetics , Tacrolimus/pharmacokinetics , Weight Gain , ATP Binding Cassette Transporter, Subfamily B , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , ATP Binding Cassette Transporter, Subfamily G, Member 2 , ATP-Binding Cassette Transporters/genetics , Adolescent , Aging , Child , Child, Preschool , Cytochrome P-450 CYP3A/genetics , Drug Dosage Calculations , Female , Graft vs Host Disease , Humans , Hypoxia/metabolism , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/blood , Infant , Male , Metabolic Clearance Rate , Neoplasm Proteins/genetics , Polymorphism, Genetic , Pulmonary Eosinophilia/metabolism , Syndrome , Tacrolimus/adverse effects , Tacrolimus/blood
9.
Br J Ophthalmol ; 92(9): 1293-6, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18723748

ABSTRACT

AIMS: The aim of this study was to investigate the association between normal tension glaucoma and the candidate disease locus glaucoma 1, open angle, B (GLC1B) on chromosome 2. There are many reports describing the results of association or linkage studies for primary open angle glaucoma (POAG), with GLC1B as one of the loci associated with normal or moderately elevated intraocular pressure. However, there are few reports about the association of genes or defined genomic regions with normal tension glaucoma, which is the leading type of glaucoma in Japan. The GLC1B locus is hypothesized to be a causative region for normal tension glaucoma. METHODS: Genomic DNA was extracted from whole blood of normal tension glaucoma (n = 143) and healthy controls (n = 103) of Japanese origin. RESULTS: Fifteen microsatellite markers within and/or near to the GLC1B locus were genotyped, and their association with normal tension glaucoma was analysed. Two markers D2S2264 and D2S176 had significant positive associations. CONCLUSION: The D2S176 marker had the strongest significant association and it is located 24 kb from the nearest gene NCK2, which now becomes an important new candidate gene for future studies of its association with normal tension glaucoma.


Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Chromosomes, Human, Pair 2/genetics , Glaucoma, Open-Angle/genetics , Microsatellite Repeats/genetics , Oncogene Proteins/genetics , Polymorphism, Genetic/genetics , Adult , DNA, Satellite , Female , Genetic Linkage/physiology , Genotype , Glaucoma/genetics , Humans , Intraocular Pressure/genetics , Male , Middle Aged , Polymerase Chain Reaction
11.
Tissue Antigens ; 70(5): 423-6, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17854429

ABSTRACT

Toll-like receptors (TLRs) play an important role in the induction of defense mechanisms of the innate and adaptive immune responses to microbial pathogens. Genetic polymorphisms within the TLR9 gene have been reported to be associated with a variety of inflammatory and infectious diseases. Behçet's disease (BD) is a chronic inflammatory disease, and the etiology of BD has yet to be fully elucidated. We investigated the potential association of the TLR9 gene with susceptibility to BD by analyzing the frequency of nine single nucleotide polymorphisms (SNPs) in a population of 200 Japanese BD patients and 102 randomized controls. Our results showed that SNPs in the TLR9 gene were not significantly associated with susceptibility to BD.


Subject(s)
Behcet Syndrome/genetics , Polymorphism, Single Nucleotide , Toll-Like Receptor 9/genetics , Asian People , Female , Genetic Predisposition to Disease , Humans , Japan , Male
12.
Ann Hum Genet ; 71(Pt 5): 630-8, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17359493

ABSTRACT

Genetic determinants of resistance to hypobaric hypoxia in the Sherpa are still unknown. Since adaptive gene variants must still be subjected to positive selection, linkage disequilibrium between such variants and specific alleles of flanking DNA markers is expected. Following this line of reasoning, we performed a human genome scan using 998 polymorphic DNA markers in 7 unrelated Sherpa porters living in the Solu-Khumbu area. This minimalist approach succeeded in detecting 8 DNA markers showing homozygosity for the same shared allele. Analysis of additional DNA samples from 2 more Sherpa porters focused our attention on three polymorphic DNA markers (D6S1697, D14S274, D17S1795) showing homozygosity for the same shared allele in 8 out 9 tested individuals. Analysis of DNA samples from Sherpa and non-Sherpa populations of Nepal proved HW equilibrium in both populations for markers D14S274 and D17S1795, while an excess of heterozygotes was observed in the Sherpa population for marker D6S1697. A significant difference in allele frequencies for D14S274 and D17S1795 between the two populations was observed. These findings exclude the possibility that homozygosity for 3 specific loci in 8 unrelated individuals might be ascribed to inbreeding or recent genetic drift. We therefore conclude that the chromosomal segments detected by such DNA markers may include genes involved in adaptation to hypobaric hypoxia.


Subject(s)
Adaptation, Physiological/genetics , DNA/genetics , Hypoxia/genetics , Polymorphism, Genetic , Computer Simulation , Genetic Markers , Humans , Models, Genetic , Nepal
14.
Tissue Antigens ; 66(3): 200-8, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16101831

ABSTRACT

Cardiomyopathy is a heart muscle disease with impaired stretch response that can result in severe heart failure and sudden death. A small proportion of hepatitis C virus (HCV)-infected patients may be predisposed to develop dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). The molecular mechanisms involved in the predisposition remain unknown due in part to the lack of information on their genetic background. Because the human leukocyte antigen (HLA) region has a pivotal role in controlling the susceptibility to HCV-induced liver disease, we hypothesized that particular HLA alleles and/or non-HLA gene alleles within the human major histocompatibility complex (MHC) genomic region might control the predisposition to HCV-associated DCM (HCV-DCM) and/or HCV-associated HCM (HCV-HCM). Here, we present mapping results of the MHC-related susceptibility gene locus for HCV-associated cardiomyopathy by analyzing microsatellite and single nucleotide polymorphism markers. To delineate the susceptibility locus, we genotyped 44 polymorphic markers scattered across the entire MHC region in a total of 59 patients (21 HCV-DCM and 38 HCV-HCM) and 120 controls. We mapped HCV-DCM susceptibility to a non-HLA gene locus spanning from NFKBIL1 to MICA gene loci within the MHC class III-class I boundary region. Our results showed that HCV-DCM was more strongly associated with alleles of the non-HLA genes rather than the HLA genes themselves. In addition, no significant association was found between the MHC markers and HCV-HCM. This marked difference in the MHC-related disease susceptibility for HCV- associated cardiomyopathy strongly suggests that the development of HCV- DCM and HCV-HCM is under the control of different pathogenic mechanisms.


Subject(s)
Cardiomyopathy, Dilated/immunology , Cardiomyopathy, Hypertrophic/immunology , Genetic Predisposition to Disease , Haplotypes , Hepacivirus/genetics , Histocompatibility Antigens Class I/genetics , RNA Helicases/genetics , Vacuolar Proton-Translocating ATPases/genetics , Adaptor Proteins, Signal Transducing , Alleles , Cardiomyopathy, Dilated/virology , Cardiomyopathy, Hypertrophic/virology , Chromosome Mapping , DEAD-box RNA Helicases , DNA Primers/genetics , Genome , Genotype , HLA Antigens/immunology , Histocompatibility Antigens Class II , Humans , Linkage Disequilibrium , Microsatellite Repeats/genetics , Models, Genetic , Odds Ratio , Polymorphism, Single Nucleotide , Promoter Regions, Genetic , Risk , Treatment Outcome
15.
Transplant Proc ; 36(2 Suppl): 299S-301S, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15041357

ABSTRACT

The calcineurin inhibitors cyclosporine and tacrolimus have distinct advantages and drawbacks. Therefore it is important to tailor their use to the patient's tolerance. In some patients, the need to ameliorate the adverse effects of tacrolimus may necessitate a switch to cyclosporine-based therapy. Rescue therapy with a cyclosporine microemulsion (Neoral)-based regimen for transplant patients intolerant of tacrolimus has been evaluated to assess the best method of switching and determine the initial and maintenance doses of Neoral in children and adults. Our aims were to evaluate not only these facets, but also the pharmacokinetics of Neoral in stable patients, including target 2-hour postdose blood concentrations (C2) of cyclosporine in liver transplant recipients. Eighteen liver transplant patients switched from tacrolimus to Neoral underwent a program of cyclosporine blood level monitoring. The conversions were conducted safely; the incidence of acute rejection episodes was low (11.1%). Statistical analysis showed that the C2 correlated with the area under the time-blood concentration curve of cyclosporine for 0 to 4 hours after dosing (R=0.970). We determined the maintenance doses of Neoral for pediatric and adult patients as well as the feasibility of C2 quantitated monitoring in liver transplantation.


Subject(s)
Cyclosporine/therapeutic use , Liver Transplantation/immunology , Tacrolimus/therapeutic use , Administration, Oral , Adolescent , Adult , Child , Child, Preschool , Cyclosporine/administration & dosage , Female , Humans , Immunosuppressive Agents/therapeutic use , Infant , Male , Middle Aged , Retrospective Studies
16.
Tissue Antigens ; 63(4): 362-8, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15009808

ABSTRACT

In order to determine whether matching/mismatching for microsatellite polymorphism provides useful information on acute graft-vs-host disease (GVHD), survival, and leukemia relapse in hematopoietic stem cell (HSC) transplantation, we genotyped for polymorphisms at 13 microsatellite loci within the major histocompatibility complex (MHC) of 100 unrelated HSC transplant donor-recipient pairs who were matched at five classical human leukocyte antigen (HLA) loci. A high percentage of allele matching was obtained for five microsatellite loci, DQCARII (96%), MICA (93%), MIB (89%), C1-3-1 (93%), and D6S510 (97%), that are localized within 100 kb of the HLA-DR, HLA-DQ, HLA-B, HLA-C, or HLA-A locus. In contrast, the other eight microsatellites are located farther away from the HLA classical loci and have much lower percentages of allele matching [e.g. tumor necrosis factor a (TNFa) (73%), TNFd (74%), D6S273 (64%), C3-2-11 (46%), C5-3-1 (50%), C5-4-5 (63%), C5-2-7 (68%), and D6S265 (81%)]. Therefore, there were at least eight microsatellite markers with relatively high percentages of mismatches in the donor/recipient pairs with acute or chronic GVHD, poor graft survival, and leukemia relapse. However, there were no statistically significant associations between mismatched donor-recipient pairs at the 13 microsatellite loci and acute or chronic GVHD, graft survival, and leukemia relapse. Nevertheless, allele matching at the microsatellite TNFd locus near the TNFa gene was found by the Fisher's exact double-sided test to be significantly associated with decreased survival in the grade III/IV acute GVHD group. Overall, these results suggest that the matching of microsatellite polymorphisms within the HLA region, especially the ones farthest from the classical HLA loci, was not useful indicator for the outcome of HSC transplantation from unrelated donors. In this regard, the future determination of the genome-wide microsatellite genotypes in HLA-matched donor-recipient pairs, outside the MHC, may be a better possibility for identifying minor histocompatibility genes in linkage disequilibria with microsatellites as potential predictive markers for the occurrence of acute GVHD and survival rate in HSC transplantation.


Subject(s)
Graft vs Host Disease/genetics , HLA-DQ Antigens/genetics , HLA-DR Antigens/genetics , Hematopoietic Stem Cell Transplantation , Histocompatibility Antigens Class I/genetics , Leukemia/therapy , Microsatellite Repeats/genetics , Adolescent , Adult , Child , Child, Preschool , Female , Genetic Markers , Graft vs Host Disease/immunology , Graft vs Host Disease/mortality , Histocompatibility Testing , Humans , Infant , Leukemia/genetics , Leukemia/immunology , Leukemia/pathology , Male , Middle Aged , Prognosis , Recurrence
17.
Tissue Antigens ; 60(5): 396-9, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12492815

ABSTRACT

We have previously suggested that in a Japanese population the susceptible locus for Behçet's disease (BD) is HLA-B51 itself. To confirm this finding in another population, we performed HLA class I typing using the PCR-SSP method and analyzed eight polymorphic markers distributed within 1100 kb around the HLA-B gene using automated sequencer and subsequent automated fragment detection by fluorescent-based technology with the DNA samples of 84 Iranian patients with BD and 87 healthy ethnically matched controls. As a result, three microsatellite alleles (MICA-A6, MIB-348, C1-4-1-217) and HLA-B51 were found to be strongly associated with BD. Of these alleles HLA-B51 is the most strongly associated allele. There were no alleles that were increased in allele frequency at any microsatellite loci centromeric of MICA or telomeric of HLA-B51. Therefore, HLA-B51 was confirmed to be by far the most strongly associated gene with BD in an Iranian population.


Subject(s)
Behcet Syndrome/genetics , HLA-B Antigens/genetics , Microsatellite Repeats , Polymorphism, Genetic , Behcet Syndrome/immunology , Chromosome Mapping , HLA-B51 Antigen , Humans , Iran
18.
Tissue Antigens ; 60(1): 53-63, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12366783

ABSTRACT

Non-obstructive azoospermia is a male infertility characterized by no or little sperm in semen as a result of a congenital dysfunction in spermatogenesis. Previous studies have reported a higher prevalence of particular human leukocyte antigen (HLA) antigens in non-obstructive azoospermia. As the expression of the RING3 gene located in the HLA class II region was predominant in the testis, mainly around spermatids and pachytene spermatocytes, it is tempting to speculate that RING3 is one of the strong candidate genes responsible for the pathogenesis of the disease. In this study, the genetic polymorphism in the RING3 gene was investigated by the direct sequencing technique. As a result, a total of 14 single nucleotide polymorphisms were identified. Among them, six were localized in the coding region but none of them was accompanied by an amino-acid substitution. No significant difference in the allelic distribution at these 14 polymorphic sites was observed between the patients and healthy controls, suggesting that the susceptible gene for non-obstructive azoospermia is not the RING3 gene. Then, in order to map the susceptibility locus for non-obstructive azoospermia precisely within the HLA region, 11 polymorphic microsatellite markers distributed from the SACM2L gene just outside the HLA class II region (187 kb telomeric of the DPB1 gene) to the OTF3 gene in the HLA class I region were subjected to association analysis in the patients. Statistical analysis of distribution in the allelic frequency at each microsatellite locus demonstrated that the pathogenic gene for non-obstructive azoospermia is located within the HLA-DR/DQ subregion. In fact, DRB1*1302 and DQB1*0604 were found to be strongly associated with non-obstructive azoospermia by polymerase chain reaction-based DNA typing. Further, haplotype analysis suggested that the DQB1*0604 allele may play a decisive role in the pathogenesis of non-obstructive azoospermia.


Subject(s)
Genetic Predisposition to Disease/genetics , HLA-DQ Antigens/classification , HLA-DQ Antigens/genetics , HLA-DR Antigens/classification , HLA-DR Antigens/genetics , Histocompatibility Antigens Class II/genetics , Oligospermia/genetics , Alleles , Base Sequence , Chromosome Mapping , Exons/genetics , Genetic Markers/genetics , HLA-DQ Antigens/physiology , HLA-DQ beta-Chains , Haplotypes/genetics , Histocompatibility Testing , Humans , Japan , Linkage Disequilibrium/genetics , Male , Microsatellite Repeats/genetics , Molecular Sequence Data , Polymorphism, Genetic/genetics , Sequence Deletion/genetics , Statistics as Topic
19.
Tissue Antigens ; 59(2): 118-21, 2002 Feb.
Article in English | MEDLINE | ID: mdl-12028538

ABSTRACT

Behçet's disease (BD) is widely known to be strongly associated with human leukocyte antigen (HLA) B51 in many different ethnic groups.Recently, HLA-B51 allele typing of Greek BD patients was performed to study the distribution of B*5101-B*5107 alleles in this Greek population, the B51 antigen strongly associated with BD was found to be predominantly encoded by allele B*5101. As it is now known that the B51 antigen can be encoded by 21 alleles, B*5101-B*5121, we performed HLA-B*51 allele genotyping among 58 Greek patients with BD. After serological HLA typing, typing of HLA-B*51 alleles was performed using the polymerase chain reaction-sequencing-based typing (PCR-SBT) method. The frequency of the B51 antigen was found to be significantly higher in the patient group as compared with the control group (75.9% of patients vs 22.0% of controls. In the genotyping of B51 alleles, 34 out of 44 B51-positive patients possessed B*5101, 13 out of the 44 carried B*5108. In contrast, all of the 9 B51-positive normal controls carried B*5101. This study revealed a strong association between Greeks with BD, both B*5101, B*5108, provided important insights into the molecular mechanism underlying the association between HLA status, this disease.


Subject(s)
Alleles , Behcet Syndrome/genetics , HLA-B Antigens/genetics , Behcet Syndrome/ethnology , Greece/ethnology , HLA-B Antigens/analysis , HLA-B Antigens/immunology , HLA-B51 Antigen , Histocompatibility Testing/methods , Humans , Molecular Sequence Data , Polymerase Chain Reaction , Sequence Analysis, DNA
20.
Tissue Antigens ; 58(3): 181-4, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11703826

ABSTRACT

Behçet's disease (BD) is known to be associated with human leukocyte antigen (HLA) B51 in many different ethnic groups. An increased incidence of HLA-B51 in the patient group has also been reported in a Japanese population. Recently, the B51 antigen has been identified to comprise 21 alleles, B*5101-B*5121. Further, not only HLA-B*5101 but also HLA-B*5108 were found to be relatively increased in the patient groups among Italian and Saudi Arabian populations. Therefore, we performed HLA-B*51 allele genotyping by the polymerase chain reaction-sequencing based typing (PCR-SBT) method in order to investigate whether there is any correlation of one particular B51-associated allele with Japanese BD. Ninety-six Japanese patients with BD and 132 healthy Japanese volunteers were enrolled in this study. As a result, the phenotype frequency of the B51 antigen was confirmed to be remarkably increased in the patient group as compared to the ethnically matched control group (59.4% in patients vs. 13.6% in controls; Pc=0.0000000000098, R.R.=9.3). In the B*51 allele genotyping, 56 out of 57 B51-positive patients were defined as B*5101 and the remaining one was B*5102. In contrast, all of 18 B51-positive normal controls were B*5101. None of the Japanese patients and healthy controls carried the HLA-B*5108 allele. This study revealed that B*51 allelic distribution in Japanese was different from those in Italian and Saudi Arabian populations, and that the significantly high incidence of the HLA-B51 antigen in the Japanese BD patient group was mostly caused by the significant increase of the HLA-B*5101 allele.


Subject(s)
Alleles , Behcet Syndrome/genetics , Genetic Predisposition to Disease , HLA-B Antigens/genetics , Gene Frequency , Genes, MHC Class I , Genotype , HLA-B51 Antigen , Histocompatibility Testing , Humans , Japan , Polymerase Chain Reaction/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...